Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $181,328.27 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 2,039 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $181,328.27. Following the sale, the chief operating officer owned 77,729 shares of the company’s stock, valued at approximately $6,912,439.97. The trade was a 2.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $83.49 on Friday. The company’s fifty day moving average is $78.80 and its two-hundred day moving average is $66.80. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of -22.69 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same period last year, the firm posted ($0.88) earnings per share. The company’s quarterly revenue was down 60.8% on a year-over-year basis. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium‑term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price‑target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical‑stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ≈$90), a material single‑day disposal that can be perceived as profit‑taking and may cap short‑term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short‑term supply and investor caution. Read More.

Analysts Set New Price Targets

Several research firms have recently commented on KYMR. Piper Sandler upped their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Truist Financial raised their price target on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Leerink Partners boosted their price objective on Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Royal Bank Of Canada restated an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Barclays increased their target price on Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently made changes to their positions in the company. Federated Hermes Inc. acquired a new position in shares of Kymera Therapeutics during the third quarter worth approximately $31,622,000. China Universal Asset Management Co. Ltd. grew its holdings in Kymera Therapeutics by 77.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock worth $1,007,000 after buying an additional 10,052 shares in the last quarter. Candriam S.C.A. increased its position in Kymera Therapeutics by 24.4% in the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after acquiring an additional 37,536 shares during the period. Frontier Capital Management Co. LLC increased its position in Kymera Therapeutics by 272.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock valued at $21,463,000 after acquiring an additional 359,847 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Kymera Therapeutics by 26.3% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock valued at $4,689,000 after acquiring an additional 22,392 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.